2024 Targeted Therapies for Lung Cancer (TTLC) - Abstracts & Posters-PP01.13 Xiao

PP01.13 Xiao - Poster

Pdf Summary

The document discusses the outcomes of patients with EGFR-mutated non-small cell lung cancer (NSCLC) who were treated with EGFR tyrosine kinase inhibitors (TKIs) followed by immunotherapy (IO). It was found that patients with "Uncommon" EGFR mutations had improved progression-free survival (PFS) with IO therapy compared to those with "Common" EGFR mutations. Notably, patients treated with IO monotherapy after progressing on EGFR TKIs did not show durable responses, suggesting a benefit from cytotoxic agents in this context. Further research on the molecular profiles associated with uncommon mutations is recommended to identify factors that enhance PFS with IO in this population.<br /><br />Overall, the study included 59 patients with a median age of 61, primarily with Stage IV disease at diagnosis. Different EGFR mutations were observed, with some patients receiving multiple EGFR TKIs. The study showed that patients who received two EGFR TKIs had similar overall survival to those who did not. Side effects of IO therapy were reported, with hepatitis, nephritis, and encephalopathy being the most common. Patients who received IO with chemotherapy had a longer median PFS compared to those who only received IO.<br /><br />In conclusion, the study highlights the potential benefit of IO therapy in patients with uncommon EGFR mutations and the importance of considering cytotoxic agents alongside IO for improved treatment responses after EGFR TKI progression. Further research is needed to explore the optimal treatment strategies for EGFR-mutated NSCLC patients.

Keywords

EGFR-mutated non-small cell lung cancer

EGFR tyrosine kinase inhibitors

immunotherapy

progression-free survival

Uncommon EGFR mutations

Common EGFR mutations

cytotoxic agents

molecular profiles

overall survival

optimal treatment strategies